Related Experiment Video
Updated: Jul 2, 2025
14:18
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
1.8K
An Update on Current Therapeutic Options in IgA Nephropathy
Regina Shaoying Lim1, See Cheng Yeo1, Jonathan Barratt2,3
1Department of Renal Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
Journal of Clinical Medicine
|February 24, 2024
Summary
Immunoglobulin A nephropathy (IgAN), a major cause of kidney disease, has seen new treatments emerge. Future strategies will combine supportive care with novel therapies targeting inflammation and fibrosis.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Immunoglobulin A nephropathy (IgAN) is the primary cause of glomerular disease globally, leading to significant chronic kidney disease and kidney failure.
- Current management relies on supportive care, including lifestyle changes and renin-angiotensin-aldosterone system blockade.
- Limited disease-specific treatments have historically been available for IgAN.
Purpose of the Study:
- To review recent advancements in therapeutic strategies for IgAN.
- To summarize new investigational agents targeting IgAN pathogenesis.
- To highlight promising discoveries for future treatment paradigms.
Main Methods:
- Literature review of recent studies on IgAN therapeutics.
- Analysis of emerging treatment targets and drug development pipelines.
- Synthesis of updated information since the 2021 review.
Main Results:
- Significant progress in understanding IgAN pathogenesis.
- Development of novel agents targeting inflammation, fibrosis, and IgA production.
- Acceptance of surrogate outcomes facilitating accelerated drug approval.
Conclusions:
- A multi-pronged treatment approach is envisioned for IgAN.
- Future strategies will integrate supportive care with targeted therapies.
- Emerging treatments offer hope for improved IgAN patient outcomes.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:27Open Angle Glaucoma: Treatment
449
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
449
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
119
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
119